The Department of War (DOW) has issued an official memorandum clarifying that federal marijuana rescheduling efforts under the Trump administration will not alter current prohibitions regarding cannabis use by military service members and civilian Department of Defense employees. Despite the shifting federal stance on cannabis classification, the Pentagon maintains that its drug-free workplace policies remain strictly in effect to ensure national security, public safety, and operational readiness. The memo underscores a critical distinction between federal administrative scheduling and internal personnel policies.
For the defense sector, the stance remains absolute: regardless of changes to the Controlled Substances Act, active-duty personnel and support staff are prohibited from using cannabis. This development serves as a reminder to stakeholders in the cannabis industry that federal rescheduling does not equate to universal legalization. Even as the executive branch moves toward rescheduling, large-scale federal employers and sectors governed by national security protocols are asserting their autonomy to maintain zero-tolerance drug policies.
This creates a clear regulatory ceiling that will likely persist for the foreseeable future, limiting the addressable consumer base among federal and military employees. Business owners should prepare for continued friction between state-legal cannabis markets and federal employment standards, as the military’s explicit refusal to align with a more lenient federal scheduling trend signals that workplace protections for cannabis consumers will remain inconsistent across different sectors of the economy.